Roche’s Biosimilar Losses Could Be Closer To CHF5bn
Management Forecast Risen Since Year Began
Roche entered the year with a projected hit to revenues from multi-source biosimilar competition to its three leading biologics. However, the number was increased at the half-year mark and could be set to ratchet up further, according to management.
